Paratek Pharmaceuticals Presents New Microbiology Efficacy Data of Oral-only Omadacycline Against the Most Common Pathogens Associated with Skin Infections

– First presentation of the OASIS-2 topline results
– Sub-analysis examining efficacy of oral-only omadacycline on lesion size also presented at ECCMID 2018
MADRID, Spain, April 23, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that an analysis of microbiology data from OASIS-2, its second Phase 3 study of omadacycline in acute skin infections, found that once-daily monotherapy with oral omadacycline is effective in treating frequently isolated pathogens associated with skin infections, including resistant Staphylococcus aureus (MRSA). These findings were presented at the annual meeting of the European Congress of Clinical Microbiology and Infectio…


Leave a Reply

Your email address will not be published.